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ABSTRACT
Background and Objectives: Percutaneous cardiopulmonary support (PCPS) has proven to be a valuable technique in high-
risk coronary patients undergoing percutaneous coronary intervention (PCI). However, there have been few studies on PCI 
associated with PCPS in Korea. We summarized our experience with PCPS-supported PCI. Subjects and Methods: We 
retrospectively reviewed 19 patients with PCPS-supported PCI between August 2005 and June 2009. PCPS was used as an 
elective procedure for 10 patients with at least two of the following conditions: left-ventricular ejection fraction <35%, target ves-
sel(s) supplying more than 50% of the viable myocardium, high risk surgical patients, and patients who refused coronary by-
pass surgery. In the remaining 9 patients PCPS was used as an emergency procedure, to stabilize and even resuscitate patients 
with acute myocardial infarction and cardiogenic shock, in order to attempt urgent PCI. Results: Among the 19 patients 
who were treated with PCPS-supported PCI, 11 (57.9%) survived and 8 (42.1%) patients did not. ST elevation myocardial 
infarction with cardiogenic shock was more prevalent in the non-survivors than in the survivors (75% vs. 27.3%, p=0.04). 
The elective PCPS-supported PCI was practiced more frequently in the survivors than in the non-survivors (72.7% vs. 25%, 
p=0.04). In the analysis of the event-free survival curve between elective and emergency procedures, there was a significant 
difference in the survival rate (p=0.025). Among the survivors there were more patients with multi-vessel disease, but a low-
er Thrombolysis in Myocardial Infarction grade in the culprit lesions was detected in the non-survivors, before PCI. Although 
we studied high-risk patients, there was no procedure-related mortality. Conclusion: Our experience suggests that PCPS 
may be helpful in high risk patients treated with PCI, especially in elective cases. More aggressive and larger scale studies of 
PCPS should follow. (Korean Circ J 2011;41:299-303)
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Introduction
Percutaneous cardiopulmonary support (PCPS) provides 
hemodynamic support via the femoral artery and vein, us-
ing a closed artificial heart-lung system which is usually com-
posed of a centrifugal pump and a membranous artificial lung.
1)2) 
In terms of cardiac failure, the most common indications for 
PCPS are post-cardiotomy (in which cardiopulmonary bypass 
cannot be taken off the patient following cardiac surgery), 
post-heart transplant (usually due to primary graft failure) and 
severe cardiac failure due to almost any other cause (eg., de-
compensated cardiomyopathy, myocarditis, acute coronary 
syndrome with cardiogenic shock, profound cardiac depres-
sion due to drug overdose or sepsis). In terms of respiratory 
failure, the most common indications include adult respirato-
ry distress syndrome, pneumonia, trauma, and primary graft 
failure following lung transplantation.
2-4) In particular, PCPS 
has proven to be a technique of value in high-risk coronary pa-
tients who undergo percutaneous coronary intervention (PCI).
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However, there have been few studies on PCPS-supported PCI 
in Korea. Thus, we summarized our experience with PCPS-
supported PCI. 
Subjects and Methods
Subjects
We combined the use of PCPS and coronary stent revascul-
arization in 19 patients between August 2005 and June 2009, 
at the Yonsei Cardiovascular Center. PCPS was used as an el-
ective procedure in 10 patients who satisfied at least two of the 
selection criteria: left ventricular ejection fraction (LVEF) 
<35%, target vessel(s) supplying more than 50% of the viable 
myocardium, high risk surgical patients {old age, impending 
end stage of renal disease, chronic obstructive pulmonary dise-
ase, a history of coronary artery bypass graft surgery (CABG)}, 
and patients who refused CABG surgery. In the remaining 9 
patients, PCPS was used as an emergency procedure to sta-
bilize and even resuscitate patients with acute myocardial 
infarction (AMI) and cardiogenic shock, in order to attempt 
urgent PCI. We compared the clinical characteristics, PCPS 
and angiographic findings, and clinical outcomes of the sur-
vivors and non-survivors. 
Percutaneous cardiopulmonary support procedure
The PCPS system used in our study was the Capiox Emer-
gency Bypass System
® (Terumo, Inc., Tokyo, Japan), which is 
an all-in-one package of a heparin-coated membrane oxy-
genator that is preassembled with bypass circuits and a cone 
for the centrifugal pump. The PCPS apparatus is ready for 
emergency use, by a well-trained team at our hospital, ready 
to prepare the patient for pump placement within minutes. 
For the percutaneous technique, the tip of the arterial cannu-
la was advanced and positioned in the common iliac artery; 
the tip of the venous catheter was placed at the junction of the 
right atrium and the superior vena cava along a rigid backup 
guidewire under the fluoroscopic guidance. The patients were 
fully heparinized with continuous injection at the rate of 3 mg/ 
kg/min, to maintain an activated clotting time greater than 
200 seconds. The pump and cannulas were purged, and ex-
tracorporeal circulation was initiated. The centrifugal pump 
provided a non-pulsatile flow at a rate between 1 and 5 L/min. 
During the procedure the flow was increased or decreased 
with inotropic drugs or fluids as needed. Then, both cannulas 
were clamped, and the pump was interrupted. At this point, 
one-to-one protamine neutralization of the circulating heparin 
was performed, allowing removal of the cannulas and prolong-
ed groin compression.
Statistics
The data are expressed as means±standard deviations for 
the continuous variables, and as absolute and relative frequ-
encies for the categorical variables. Student’s unpaired t-test 
was used to compare the continuous variables between the 
groups. Categorical variables were compared with using the 
Chi-square test. Event-free survival curves were constructed 
by the use of the Kaplan-Meier method. Probability values 
<0.05 were considered to be statistically significant.
 
Results 
Patient clinical characteristics
The demographics and pre-existing co-morbidities were 
similar between the survivors and non-survivors. Unstable an-
gina and non-ST elevation myocardial infarction patients were 
more common among the survivors; ST elevation myocardial 
infarction (STEMI) with cardiogenic shock was more preva-
lent in the non-survivor group compared to the survivors (75% 
vs. 27.3%, p=0.04). EF was not significantly different between 
the survivors and non-survivors. The cardiac biomarkers (crea-
tine kinase-MB, N-terminal pro-B-type natriuretic peptide) were 
not significantly different between the survivors and non-sur-
vivors either (Table 1).
Percutaneous cardiopulmonary support and 
angiographic findings
The elective PCPS-supported PCI was more frequently pr-
acticed among the survivors compared to the non-survivors 
(72.7% vs. 25%, p=0.04). All patients were weaned from PC-
PS in the survivor group and 6 (75%) patients were weaned 
from PCPS among the non-survivors. The median durations 
of PCPS support were not significantly different between the 
survivors and non-survivors. There were no significant dif-
Table 1. Clinical characteristics of the study patients
Survivors
(n=11)
Non-survivors
(n=8)
p
Age (years) 69.3±10.4 66.8±14.1 0.685
Male 8 (72.7) 6 (75)0. 0.912
Diabetes mellitus 6 (54.5) 5 (62.5) 0.729
Hypertension 8 (72.7) 5 (62.5) 0.636
Smoking 3 (27.3) 1 (12.5) 0.435
Chronic kidney disease 4 (36.4) 3 (37.5) 0.960
Cerebral vascular accident 1 (9.1)0 2 (25)0. 0.348
Unstable angina 2 (18.2) 0 (0)00. 0.202
NSTEMI 6 (54.5) 2 (25)0. 0.198
STEMI with cardiogenic 
  shock
3 (27.3) 6 (75)0. 0.040
Ejection fraction 23.2±10.1 23.3±11.9 0.990
CK-MB (ng/mL) 209±372 97±69 0.351
NT-proBNP (pg/mL) 9,017±9,983 12,781±14,746 0.544
Values are in n (%) or mean±standard deviation. NSTEMI: non-
ST elevation myocardial infarction, STEMI: ST elevation myocar-
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ferences in culprit lesions between the survivors and non-
survivors. More patients with multi-vessel disease were in the 
survivors than in the non-survivors (90.9% vs. 50%, p=0.046), 
however, a lower Thrombolysis in Myocardial Infarction (TI-
MI) grade (0-1) in the culprit lesions before PCI was detected 
among the non-survivors. After PCI, TIMI grade 3 was main-
tained in all patients. There were no significant differences in 
the use of Intra-aortic balloon pump (IABP) or in the number 
of stents between the survivors and non-survivors (Table 2).
Clinical outcomes and complications
Patients who survived were discharged from the hospital 
and closely followed at the outpatient department. The mean 
clinical follow-up period was 541.1±548.6 days. Overall in-
hospital mortality was 31.6% (6 of 19), of which 4 deaths were 
cardiac-related and 2 were not. The causes of non-cardiac-re-
lated deaths were sepsis associated with pneumonia and up-
per gastrointestinal bleeding (Table 3). We also compared the 
survival rates of patients who underwent elective procedure 
and emergency procedure. In the analysis of the event free sur-
vival curve between elective procedure and emergency pro-
cedure, there were significant differences in the survival rate 
(p=0.025) (Fig. 1). Although we studied high-risk patients, th-
ere was no procedure-related mortality. The most common 
complications were hematomas near the catheter insertion 
site, which disappeared by the time of discharge from hospital. 
One patient who underwent emergency procedure had lower 
limb ischemia and gangrene, but survived without sequelae. 
 
Discussion
Based on the results of previous studies the application of 
PCPS-supported PCI on high risk patients with severe LV 
dysfunction is accepted as helpful.
5-9) PCPS provides com-
plete systemic hemodynamic support independent of intrinsic 
cardiac function and rhythm, and has been successfully used 
prophylactically in high-risk patients during PCI. This pre-
ventative support allows for precise diagnostic and therapeu-
tic occlusive maneuvers {e.g., Intravascular ultrasound (IV-
US), kissing balloon of bifurcated lesions} while preserving 
systemic perfusion pressures, and preventing both circulato-
ry collapse and malignant arrhythmia.
10)11) In one study, alth-
ough it was from a small number of patients, the authors re-
commended prophylactic cardiopulmonary bypass support 
in unstable patients undergoing angioplasty with EF <25%, 
or in patients whose EF is low and in whom the only patent 
Table 2. PCPS and angiographic findings of the study patients
Survivor
(n=11)
Non-survivors
(n=8)
p
Elective case  08 (72.7) 2 (25)0. 0.040
PCPS weaning 11 (100) 6 (75)0. 0.080
PCPS time (minutes) 1,394±2,540 2,112±2,269 0.527
Culprit lesions
LAD 06 (54.5) 5 (62.5) 0.729
LCx 06 (54.5) 5 (62.5) 0.729
RCA 04 (36.4) 2 (25)0. 0.599
Lt main 04 (36.4) 3 (37.5) 0.960
No. of diseased vessels
Multi-vessels 10 (90.9) 4 (50)0. 0.046
Lt main 04 (36.4) 4 (50)0. 0.552
Pre TIMI grade
0-1 04 (36.4) 6 (75)0. 0.096
2-3 07 (63.6) 2 (25)0. 0.096
Post TIMI grade
3 11 (100) 8 (100)
Stent (n) 2.6±1.6 2.3±1.5 0.599
IABP 03 (27.3) 2 (25)0. 0.912
Values are in n (%) or mean±standard deviation. PCPS: percutane-
ous cardiopulmonary support, LAD: left anterior descending cor-
onary artery, LCx: left circumflex coronary artery, RCA: right coro-
nary artery, Lt main: left main trunk, TIMI: Thrombolysis In Myo-
cardial Infarction, IABP: intra-aortic balloon pump
Table 3. Clinical outcomes of the study patients 
Mean follow-up duration (days) 541.1±548.6
All cause mortality 8 (42.1)
In-hospital mortality 6 (31.6)
Elective case group 1 (5.3)0
Emergency case group 5 (26.3)
Cardiac-related death 4 (21.1)
Elective case group 0 (0)00.
Emergency case group 4 (21)0.
Non cardiac-related death 4 (21.1)
Elective case group 2 (10.5)
Emergency case group 2 (10.5)
Values are in n (%) or mean±standard deviation
Fig. 1. Kaplan-Meier survival curve of elective case group and 
emergency case group.
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artery is the target of dilatation.
12) Even stable patients with EF 
<20% may benefit from prophylactic cardiopulmonary by-
pass support.
7) PCPS may also be helpful when used as an em-
ergency procedure to recover hemodynamic stability in pa-
tients with AMI and cardiogenic shock. PCPS markedly de-
creases myocardial oxygen consumption and work, creating 
favorable hemodynamic conditions to impede progression 
of myocardial infarction. Complications such as ventricular ar-
rhythmias frequently appear in cardiogenic shock and are also 
transient and reversible under PCPS. Once the patient is sta-
bilized, a coronary angiogram can be safely performed, after 
which a planned reperfusion and stent revascularization can 
be accomplished.
13-15) In 1995, Ha et al.
16)  reported, for the 
first time, a successful case of PCPS-supported PCI on a high 
risk patient. In 2006, Rhee et al.
17) reported the effectiveness of 
PCPS on patients with cardiac arrest or cardiogenic shock.
We analyzed, for the first time in Korea, the high-risk pa-
tients who underwent PCPS-supported PCI, being the elec-
tive case group and emergency case group. Even though the 
patients in both groups had similar pre-existing co-morbidi-
ties and lower EF, the patient conditions were quite different. 
Those in the emergency group were in shock status even af-
ter inotropic drug administration, while patients in the elec-
tive group were in a relatively stable condition (under gener-
al anesthesia, transfusion, etc.). For this reason, among the 
survivors, the number of patients who underwent elective 
PCPS-supported PCI was significantly higher than among 
the non-survivors. Also the in-hospital mortality rate was 
lower in the elective case group.
In this study, elective PCPS-supported PCI was applied on 
10 patients exhibiting at least two of the following condi-
tions: LVEF <35%, target vessel(s) supplying more than 50% 
of the viable myocardium, high risk surgical patients and th-
ose who refused coronary bypass surgery. PCPS was weaned 
off from all patients without serious procedure-related com-
plications and there was no procedure-related mortality. Due 
to underdevelopment of vascular device and stenting techno-
logy in the past, procedure-related complications were com-
mon in high risk patients who were subjected to application 
of LV assist.
18) In this study, the use of a more advanced vascu-
lar device helped reducing procedure-related complications. 
All patients received drug-eluting stents and even IVUS was 
done if necessary. We could expect a more favorable progno-
sis with elective PCPS-supported PCI on high risk patients.
In the case of emergency PCPS-supported PCI, urgent 
PCI was done to stabilize in patients who showed signs of ST-
EMI with cardiogenic shock and cardiac arrest. PCPS was 
weaned off quite successfully (in 78% patients) after its applic-
ation. However, the prognosis was not favorable, resulting in 
44.4% of cardiac related death and 55.6% of in-hospital mor-
tality. According to the results of previously published data, 
AMI with cardiogenic shock led to a ≥80% mortality rate, and 
IABP, though still applied to lower the mortality rate, result-
ed a relatively high mortality rate.
13)19) In this study, we were 
unable to restore cardiogenic shock of 5 patients by applying 
IABP alone, thus need a PCPS-support. In other studies PC-
PS-supported PCI in emergency cases was more successful 
than that with IABP support alone.
18) Three patients of this 
study survived after PCPS application and are now under out-
patient department follow-up. However, further study about 
the benefits of this procedure will be needed, considering the 
small number patients, and their conditions (vital sign, co-
morbidities, etc.), in this study. 
 
Limitation of this study
Our study has some limitations: first, this is a retrospective 
observational analysis of a relatively very small number of 
patients. Second, in the elective case group, we have not yet 
demonstrated that this approach is necessary or superior to 
unsupported angioplasty or to IABP, or to coronary bypass 
surgery where feasible. A randomized trial of supported ver-
sus unsupported (with cardiopulmonary support on stand-
by) angioplasty maybe warranted. Third, in the emergency 
case group, we have applied IABP first in most of our cases, 
thus it is hard to conclude that the benefits came from PCPS 
alone. 
Conclusion
Our experience suggests that PCPS may be helpful in high-
risk patients being or to be treated with PCI, especially in the 
elective cases. However, PCPS-supported PCI still bears con-
siderable risks in the emergent cases. To this day, a clear guide-
line or indication criteria have not been established for PCPS 
guided PCI. More aggressive and larger scale studies of PC-
PS will be needed. 
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